NasdaqCM:BSGM

Stock Analysis Report

Executive Summary

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has BioSig Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.0%

BSGM

-0.003%

US Medical Equipment

1.3%

US Market


1 Year Return

50.2%

BSGM

11.9%

US Medical Equipment

5.9%

US Market

Return vs Industry: BSGM exceeded the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: BSGM exceeded the US Market which returned 5.9% over the past year.


Shareholder returns

BSGMIndustryMarket
7 Day-7.0%-0.003%1.3%
30 Day-13.3%-3.0%-1.9%
90 Day-15.4%-0.6%-1.8%
1 Year50.2%50.2%12.8%11.9%8.3%5.9%
3 Year86.7%86.7%69.6%64.5%45.6%36.2%
5 Yearn/a129.6%104.0%66.1%47.9%

Price Volatility Vs. Market

How volatile is BioSig Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSig Technologies undervalued compared to its fair value and its price relative to the market?

14.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BSGM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: BSGM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BSGM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BSGM is overvalued based on its PB Ratio (14.9x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is BioSig Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioSig Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioSig Technologies performed over the past 5 years?

-17.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BSGM is unprofitable, and losses have increased over the past 5 years at a rate of -17.7% per year.

Accelerating Growth: Unable to compare BSGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BSGM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: BSGM has a negative Return on Equity (-222.66%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BSGM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BSGM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is BioSig Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BSGM's short term assets ($10.6M) exceeds its short term liabilities ($1.4M)

Long Term Liabilities: BSGM's short term assets (10.6M) exceeds its long term liabilities (468.3K)


Debt to Equity History and Analysis

Debt Level: BSGM is debt free.

Reducing Debt: BSGM currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: BSGM has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BSGM's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BSGM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BSGM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35.6% each year


Next Steps

Dividend

What is BioSig Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BSGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BSGM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BSGM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSGM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BSGM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of BioSig Technologies's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Ken Londoner (51yo)

2.3yrs

Tenure

US$2,235,967

Compensation

Mr. Kenneth L. Londoner, also known as Ken, MBA, founded BioSig Technologies, Inc. in 2009 and has been its Chief Executive Officer since July 2017. Mr. Londoner has been Managing Partner of Endicott Manag ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Ken's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.3yrs

Average Tenure

58yo

Average Age

Experienced Management: BSGM's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

4.6yrs

Average Tenure

54yo

Average Age

Experienced Board: BSGM's board of directors are considered experienced (4.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$29,25210 Jun 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares4,650
Max PriceUS$6.31
BuyUS$42,18003 Jun 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares6,000
Max PriceUS$7.03
BuyUS$31,56631 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares4,400
Max PriceUS$7.17
BuyUS$28,19729 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares4,100
Max PriceUS$7.07
BuyUS$66,70028 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares10,000
Max PriceUS$6.67
BuyUS$41,26024 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares6,000
Max PriceUS$6.89
BuyUS$68,60822 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares9,400
Max PriceUS$7.30
BuyUS$116,63320 May 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares15,000
Max PriceUS$7.78
BuyUS$77,20823 Jan 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares17,700
Max PriceUS$4.65
BuyUS$4,20023 Jan 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares1,000
Max PriceUS$4.20
BuyUS$37,25111 Jan 19
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares8,500
Max PriceUS$4.48
BuyUS$31,52323 Nov 18
Kenneth Londoner
EntityIndividual
Role
Chief Executive Officer
Founder
Shares8,500
Max PriceUS$3.80
BuyUS$3,80223 Nov 18
Steven Chaussy
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max PriceUS$3.80

Ownership Breakdown


Management Team

  • Ken Londoner (51yo)

    Founder

    • Tenure: 2.3yrs
    • Compensation: US$2.24m
  • Budimir Drakulic (69yo)

    Chief Scientist

    • Tenure: 10.7yrs
    • Compensation: US$243.75k
  • Steve Chaussy (65yo)

    Chief Financial Officer

    • Tenure: 8.4yrs
    • Compensation: US$856.25k
  • Lora Mikolaitis (46yo)

    Vice President of Administration

    • Tenure: 0yrs
    • Compensation: US$147.00k
  • Natasha Drapeau

    Executive Vice President

    • Tenure: 2.4yrs
  • Tiffini Wittwer

    Chief Regulatory & Compliance Officer

    • Tenure: 1.9yrs
  • John Kowalski

    Vice President of Sales

    • Tenure: 0.7yrs
  • Olivier Chaudoir

    Director of Marketing

    • Tenure: 0.3yrs

Board Members

  • Ken Londoner (51yo)

    Founder

    • Tenure: 2.3yrs
    • Compensation: US$2.24m
  • Jeff O'Donnell (59yo)

    Lead Director

    • Tenure: 0.8yrs
    • Compensation: US$266.50k
  • Jerry Zeldis (69yo)

    Director

    • Tenure: 0.4yrs
  • David Weild (62yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$227.28k
  • Andrea Natale

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Andy Filler (52yo)

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: US$317.19k
  • Patrick Gallagher (54yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$133.25k
  • Kalyanam Shivkumar (50yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: US$259.87k
  • Samuel Asirvatham

    Member of Scientific Advisory Board

    • Tenure: 5.8yrs
  • K. Venkatachalam

    Member of Scientific Advisory Board

    • Tenure: 4.8yrs

Company Information

BioSig Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSig Technologies, Inc.
  • Ticker: BSGM
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$154.226m
  • Shares outstanding: 22.03m
  • Website: https://www.biosig.com

Number of Employees


Location

  • BioSig Technologies, Inc.
  • 54 Wilton Road
  • 2nd Floor
  • Westport
  • Connecticut
  • 6880
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSGMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2014

Biography

BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:40
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.